Masimo Corporation is set to announce its latest quarterly earnings on Monday, May 4th, with a consensus estimate EPS of 1.41.
In today's trading session, Masimo (MASI) is priced at $178.48, showing a decrease of -17.66 cents (-0.099%) from the previous close. The trading volume is notable at $470,705, reflecting a 28.83% increase relative to the average.
The company previously reported earnings on Wednesday, February 25th, with a consensus estimate EPS of 1.52. The latest quarterly revenue and earnings call summary are pending.
Masimo's cash flow dynamics show free cash flow of $53.4 million, debt repayment of $35.3 million, and a net change in cash of -$162.4 million.
The income statement reveals a gross profit of $247.3 million, operating income of $83.9 million, and a net income of $68.3 million, resulting in an EPS of $1.25.
Key ratios indicate a net profit margin of 16.56%, return on equity of 9.47%, and a price-to-earnings ratio of 25.
The balance sheet highlights total assets of $1.70 billion, total liabilities of $977.7 million, and net debt of $407 million.
This comprehensive financial analysis provides valuable insights into Masimo Corporation's current financial status, performance, and upcoming earnings. Stay tuned for more updates on this developing story.
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.